Keywords: Dainippon Sumitomo, Shionogi, DSP-8153, Irbesartan, Amlodipine, Antihypertensive, Japan, Co-marketing
Dainippon Sumitomo Pharma and Shionogi to co-market antihypertensive DSP-8153
Article | 11 June 2012
Dainippon Sumitomo Pharma (DSP; TYO: 4506) has entered into a license accord with fellow Japanese drugmaker Shionogi (TYO: 4507) for the co-marketing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
